Purpose/Objective: to review data for patients with stage T4 and/or M1 lym esophageal cancer who have been treated with definitive chemoradiotherapy since 2000 in an institution that is one of high volume centers in Japan.
Materials and Methods:
We retrospectively reviewed data for all patients with T4 and/or M1 lym esophageal cancer who had been treated by definitive chemoradiotherapy between 2000 and 2013 in Tohoku University Hospital. The eligibility criteria included 1) histopathologically proven esophageal cancer, 2) T4 and/or M1 lymph (UICC 2002) , 3) having undergone at least 1 cycle of concomitant chemotherapy, 4) having been irradiated with 50 or more Gy, and 5) no other active malignant tumor during treatment. Survival estimates were calculated from the first day of radiotherapy using the Kaplan-Meier method, and differences were evaluated by the log-rank test. Statistical significance was defined as a value of p<0.05 in the present study. SPSS software for Windows version 20.0 was used for all calculations. Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0). Results: Data for 86 patients were used for analysis in this study. Median age of the patients was 66 years. Primary sites were in the cervical, upper thoracic, middle thoracic, lower thoracic and abdominal esophagus in 9 patients, 20 patients, 49 patients, 7 patients and 1 patient, respectively. Clinical stages were III in 54 patients, IVa in 5 patients and IVb in 27 patients. Median total irradiation dose was 60 Gy (range, 50-70 Gy). CDDP+5-FU, CDGP+5-FU, CDDP+5-FU+DOC and CDGP+DOC were performed as concomitant chemotherapy with radiotherapy in 47, 35, 2 and 2 patients, respectively. Median observation period for the survivors was 36.1 months. At the last observation date, there were 68 deaths including 5 intercurrent deaths. The 1-year and 3-year overall survival rates were 40.1% (95%CI=29.5-50.7%) and 22.4% (95%CI=13.0-31.8%), respectively. Three patients had grade 3 radiation pneumonitis and 1 patient developed grade 5 radiation pneumonitis. One patient showed grade 3 pleural effusion. The overall survival of patients without M1 lym was significantly better than that of patients with Ml lym (3-y, 32.3% (95%CI=19.0-45.6%) vs. 6.7% (95%CI=0-15.7%, p=0005). The overall survival in recent patients (2007) (2008) (2009) (2010) (2011) (2012) (2013) Purpose/Objective: The optimal waiting period between completion of neoadjuvant therapy and surgery in locally advanced rectal cancer (LARC) is controversial. The recommended duration and its impact in surgical radicality is discussed. The specific purpose of this study is to evaluate the effect of surgical interval on cancer response: tumor regression grade (TRG), postoperative morbidity and longterm oncologic outcomes.
Retrospective data analysis from patients with clinical stage II-III treated with chemoradiation (CRT) followed by surgery and IORT, between February 1995 and December 2012 is reported. Two groups according to the interval between neoadjuvant therapy and surgery (< 6 and ≥ 6 weeks) are evaluated. Clinico-pathological data related to response patterns as well as survival were compared. Results: Three hundred thirty-five patients were assessed, of which 59,4% underwent delayed surgery. Baseline characteristics of the study groups, showed a higher proportion of patients with increased oncologic risk factors in the delayed surgery group (cT4, 14,1% vs 18%; cN+, 64,1% vs 76,6%). Complete pathological response (ypT0N0) and TRG 3-4 categories incidence are not significantly different among groups (8,8% vs 12,1%, p = 0,348; 41% vs 50,8%, p = 0.082), respectively. The maximal dimension of residual tumor postneoadjuvant treatment was influenced by surgical period (p = 0.006). Longer surgical interval did not affect incidence or severity of complications or length of hospital admission (9,50 vs 10 days; p = 0.093). After a median follow-up time of 71 months, delayed surgery had a significant impact on overall survival (55,9% vs 70,4%; p = 0,014), not observed in disease-free survival (69,9% vs 74,9%; p = 0,233) or local relapse-free survival (LRFS) (90,4% vs 94,5%; p = 0,123).
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Conclusions: A modest surgical interval prolongation more than 6 weeks was safe, did not negatively affect response or oncologic outcomes and was identified as independent favourable prognostic factor for overall survival. Randomized studies are justified to explore more significant delayed time intervals between neoadjuvant CRT and surgery in LARC.
EP-1197
Clinical outcome and toxicity of 3D-conformal radiotherapy combined with chemotherapy for gastric cancer K. Preoperative radiation therapy was delivered in all patients with a total dose of 45 Gy, associated at fluoropyrimidine (5Fluorouracil + folic acid in 30 patients, Capecitabine in 22 patients), followed by surgical resection in eight weeks in all patients. The treatment tolerance was evaluated according to the NCI-CTC version 3 toxicity criteria. Therapeutic efficiency was evaluated by histopathological postoperative specimen examination. Kaplan-Meyer survival curves were defined for each polymorphism in our series.
Results:
The distribution of the three genotypes CT, CC and TT were respectively (32.6%, 48% and 19.2%). The risk of developing severe (grade 3-4) toxicity was observed in 677 CC (9,6%), 677CT(7,6%) and 677TT (3,8%). T-level downstaging after neoadjuvant treatment was demonstrated in 63.3% of cases in patients with 677TT genotype, it was 40% in 677CT genotype and 58.8% in 677CC genotype. No association is observed between C677T polymorphism and survival (log rank= 0.02, p = 0.99).
Conclusions:
In spite of the limited patient number, our study shows that the MTHFR 677 TT genotype can have a protective role of fluoropyrimidine toxicity, and it can be a predictive factor in therapeutic efficiency. This study will be continued, in order to include more patients and to analyze the second polymorphism in MTHFR gene (1298 A>C).
